摘要
我们已经进入了一个丙型肝炎病毒治疗的新时期,感染和疾病的消除成为可能。HCV细胞培养模型有助于鉴定治疗靶点,检测候选药物和治疗策略。在此我们介绍了目前针对HCV的新颖的细胞培养系统方法,允许调查HCV生命周期和复制、繁殖所需的病毒-宿主相互作用。在培养感染性病毒病从特定个体中产出肝细胞细胞系的方案的发展有潜力研究由病毒开发的传播感染的的机制以及HCV复制和繁殖或者抵抗感染的宿主因素。由于宿主因子可能是保守的,并且与不同的HCV分离株和基因型同样相互作用,所以针对病毒复制必不可少的宿主因子的药物开发在进一步提高治疗效果方面具有很大的前景。重视治疗目标也影响了体外诊断。抗HCV治疗的主要目标是在治疗结束后的12-24周,在血清或血浆中实现定义为“不可检测”的HCV-RNA基因组的持续病毒学应答。直接抗病毒剂的使用已经大大地改变了用于定义SVR的病毒载量的阈值,并导致如文本讨论的结果和临床批准的定量分子测定要求的重新评估。
关键词: 细胞培养衍生的HCV, 丙型肝炎病毒,HCV细胞培养系统,诱导多能干细胞,分子诊断,假颗粒,定量分子试验,复制。
图形摘要
Current Drug Targets
Title:How Current Direct-Acting Antiviral and Novel Cell Culture Systems for HCV are Shaping Therapy and Molecular Diagnosis of Chronic HCV Infection?
Volume: 18 Issue: 7
关键词: 细胞培养衍生的HCV, 丙型肝炎病毒,HCV细胞培养系统,诱导多能干细胞,分子诊断,假颗粒,定量分子试验,复制。
摘要: We have entered a new era of hepatitis C virus (HCV) therapy in which elimination of infection and disease is a real possibility. HCV cell culture models were instrumental for identification of therapeutic targets, testing candidate drugs, and profiling of therapeutic strategies. Here we describe current and novel methods of cell culture systems for HCV that are allowing investigation of HCV life cycle and virus-host interaction required for replication and propagation. The development of protocols to grow infectious virus in culture and generate hepatocyte cell lines from specific individuals hold great promise to investigate the mechanisms exploited by the virus to spread the infection and the host factors critical for HCV replication and propagation, or resistance to infection. Since host factors are presumably conserved and equally interacting with different HCV isolates and genotypes, the development of drugs targeting host factors essential for virus replication holds great promises in further increasing treatment efficacy. Refocusing of therapeutic goals also impacted in vitro diagnosis. The primary goal of anti-HCV therapy is to achieve a sustained virologic response (SVR) defined as “undetectable” HCV RNA genome in the serum or plasma at 12 to 24 weeks following the end of treatment. Use of direct antiviral agents has substantially changed the threshold of the viral load used to define SVR and led to a reassessment, as discussed herein, of result interpretation and requirements of clinically-approved, quantitative molecular assays.
Export Options
About this article
Cite this article as:
How Current Direct-Acting Antiviral and Novel Cell Culture Systems for HCV are Shaping Therapy and Molecular Diagnosis of Chronic HCV Infection?, Current Drug Targets 2017; 18 (7) . https://dx.doi.org/10.2174/1389450116666150806123119
DOI https://dx.doi.org/10.2174/1389450116666150806123119 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers